Search results
Results From The WOW.Com Content Network
Major coronavirus treatments and vaccine maker executives were interviewed on CNBC Monday to discuss their company's progress in the battle against the disease.Gilead CEO On Remdesivir: Gilead ...
Gilead Sciences Inc. (NASDAQ:GILD) has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials. The ...
The coronavirus crisis is putting new pressure on big pharma to contain price inflation related to potential treatments and vaccines. Gilead's breakthrough coronavirus drug sparks concerns over ...
Gilead Sciences, Inc. (/ ˈ ɡ ɪ l i ə d /) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
On November 9, 2020, Pfizer announced that BioNTech's COVID-19 vaccine, tested on 43,500 people, was found to be 90% effective at preventing symptomatic COVID-19. [127] The efficacy was updated to 95% a week later. [128] Akiko Iwasaki, an immunologist interviewed by The New York Times, described the efficacy figure as "really a spectacular number."
How COVID‑19 vaccines work. The video shows the process of vaccination, from injection with RNA or viral vector vaccines, to uptake and translation, and on to immune system stimulation and effect. Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths ...
PHOTO: In this April 16, 2021, file photo, a vial of the Moderna Covid-19 vaccine and syringes sit prepared at a pop up vaccine clinic at the Jewish Community Center in the Staten Island borough ...
The WHO has developed a multinational coalition of vaccine scientists defining a Global Target Product Profile (TPP) for COVID-19, identifying favorable attributes of safe and effective vaccines under two broad categories: "vaccines for the long-term protection of people at higher risk of COVID-19, such as healthcare workers", and other ...